|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date12 Apr 2019 |
|
MechanismMuscle-type nAChRs agonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date13 Jan 1984 |
Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis
Chronic rhinitis (CR) is one of the most common nasal mucosal diseases in the world. In China, about 140 million people suffer from this disease. Chronic rhinitis can lead to severe economic and social burden, as well as the potential risk of developing other chronic diseases such as asthma and chronic sinusitis. Therefore, it is of great significance to explore the classification and treatment strategies of chronic rhinitis in order to improve the health level of Chinese people.
100 Clinical Results associated with Shanghai Johnson & Johnson Pharmaceutical Ltd.
0 Patents (Medical) associated with Shanghai Johnson & Johnson Pharmaceutical Ltd.
100 Deals associated with Shanghai Johnson & Johnson Pharmaceutical Ltd.
100 Translational Medicine associated with Shanghai Johnson & Johnson Pharmaceutical Ltd.